Juan Pablo Alderuccio

Author

Sylvester Comprehensive Cancer Center ORCID

Also Known As

Alderuccio, Juan Pablo, F.-W. Kreth, J. Alderuccio, J. P. Alderuccio, J.P. Alderuccio, Juan Alderuccio, Juan P Alderuccio, Juan P. Alderuccio, Juan Pablo Alderuccio

178

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Sylvester Comprehensive Cancer Center University of Miami The University of Texas MD Anderson Cancer Center Washington University in St. Louis Cornell University

About

Juan Pablo Alderuccio is an author at Sylvester Comprehensive Cancer Center specializing in medicine, pathology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	659
2	Immunology	8	8	546
3	Health Sciences	2	2	93
4	Cell Biology	2	2	24
5	Epidemiology	1	1	23

Juan Pablo Alderuccio

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial Paolo F. Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio, The Lancet Oncology Loncastuximab TesirineLymphoid NeoplasiaHematological MalignancyMedicineImmunology	2021	397
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers Andrew M. Evens, Alexey V. Danilov, Deepa Jagadeesh, Blood	2021	122
Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution Juan Pablo Alderuccio, Wei Zhao, Amrita Desai, Journal of Clinical Oncology	2018	75
Bilateral radiation therapy followed by methotrexate‐based chemotherapy for primary vitreoretinal lymphoma Macarena I. de la Fuente, Juan Pablo Alderuccio, Isildinha M. Reis, American Journal of Hematology Methotrexate‐based ChemotherapyPrimary Vitreoretinal LymphomaSurgical OncologyOcular DiseaseBilateral Rt	2019	59
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis Juan Pablo Alderuccio, Adam J. Olszewski, Andrew M. Evens, Blood Advances	2021	51
Maintenance rituximab or observation after frontline treatment with bendamustine‐rituximab for follicular lymphoma Brian T. Hill, Loretta J. Nastoupil, Allison Winter, British Journal of Haematology	2018	48
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study Adam Zayac, Andrew M. Evens, Alexey V. Danilov, Haematologica	2021	40
Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma Juan Pablo Alderuccio, Amrita Desai, Monica Yepes, Clinical Case Reports Lymphoid NeoplasiaBreast OncologySaline Implant PlacementMedicineSurgical Pathology	2018	38
EBV‐positive HIV‐associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features Jennifer R. Chapman, Alyssa Bouska, Weiwei Zhang, British Journal of Haematology ImmunodeficienciesImmunologyPathologyImmunotherapyEpstein-barr Virus	2021	37
Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation Juan Pablo Alderuccio, Wei Zhao, Amrita Desai, American Journal of Hematology ImmunodeficienciesImmunologyPathologyMg. Mms PatientsHematological Malignancy	2019	34

Page 1